<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421120</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2015-0107</org_study_id>
    <nct_id>NCT02421120</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients</brief_title>
  <official_title>A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph Kuti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Christopher's Hospital for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is established evidence that adult patients with Cystic Fibrosis (CF) may have altered
      antibiotic pharmacokinetics compared with non-CF patients. Ceftolozane/Tazobactam is a newly
      approved broad spectrum intravenous antibiotic, which has potent in vitro activity against
      multidrug resistant Pseudomonas aeruginosa, the most common pathogen implicated in CF
      pulmonary exacerbations. This study will determine the pharmacokinetics and tolerability of
      ceftolozane/tazobactam in 20 adult CF patients admitted for a pulmonary exacerbation at one
      of 4 participating hospitals in the US. Patients will remain on standard of care IV
      antibiotics and receive 4-6 doses of ceftolozane/tazobactam 3 grams every 8 hours. Blood will
      be sampled after the final dose to determine concentrations and pharmacokinetics of
      ceftolozane and tazobactam. Safety and tolerability will be assessed throughout the 3 day
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive 4-6 doses of ceftolozane/tazobactam 3 grams every 8 hours, in
      addition to standard intravenous antibiotic therapy selected by the site. Just prior and then
      after the final dose, a total of six blood samples will be collected to measure ceftolozane
      and tazobactam concentrations. Data will be fit to a population pharmacokinetic model. The
      final model will be utilized in a Monte Carlo simulation to determine the probability of
      several different dosing regimens retaining concentrations above the minimum inhibitory
      concentration (MIC) for at least 39% of the dosing interval. These data will be utilized to
      determine an optimized dosing regimen for adults with CF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ceftolozane Clearance</measure>
    <time_frame>0, 1-1.08, 1.25-1.5, 2-3, 4-5, and 7-8 hours after start of final dose</time_frame>
    <description>This outcome determines the clearance of ceftolozane over the 8 hour dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceftolozane Volume of Distribution (Central Compartment)</measure>
    <time_frame>0, 1-1.08, 1.25-1.5, 2-3, 4-5, and 7-8 hours after start of final dose</time_frame>
    <description>This outcome determines the volume of distribution of ceftolozane over the 8 hour dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tazobactam Clearance</measure>
    <time_frame>0, 1-1.08, 1.25-1.5, 2-3, 4-5, and 7-8 hours after start of final dose</time_frame>
    <description>This outcome determines the clearance of tazobactam over the 8 hour dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tazobactam Volume of Distribution (Central Compartment)</measure>
    <time_frame>0, 1-1.08, 1.25-1.5, 2-3, 4-5, and 7-8 hours after start of final dose</time_frame>
    <description>This outcome determines the volume of distribution of tazobactam over the 8 hour dosing interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ceftolozane Probability of Target Attainment at 8 mcg/ml</measure>
    <time_frame>24 hours</time_frame>
    <description>This simulated outcome indicates the likelihood that ceftolozane will retain drug concentrations above the MIC for &gt;/= 60% of the dosing interval at an MIC of 8 mcg/ml when administered as a 3g (2g ceftolozane/1g tazobactam) every 8 hour dose infused over 1 hour. This analysis is conducted via a Monte Carlo simulation using the population pharmacokinetic parameter estimates and dispersion from the 20 participants who contributed pharmacokinetic data to the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability (Changes in Serum Chemistry, Hematology and Hepatic Lab Values, as Well as Reported Adverse Events)</measure>
    <time_frame>3 days</time_frame>
    <description>This outcome will assess the safety and tolerability of ceftolozane/tazobactam in adults with CF after 4-6 doses, as measured by changes in serum chemistry, hematology and hepatic lab values, as well as reported adverse events by patients and providers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Cystic Fibrosis Pulmonary Exacerbation</condition>
  <condition>Pseudomonas Aeruginosa Infection</condition>
  <arm_group>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/Tazobactam</intervention_name>
    <description>1 hour intravenous infusion</description>
    <arm_group_label>Ceftolozane/Tazobactam</arm_group_label>
    <other_name>Zerbaxa</other_name>
    <other_name>CXA-101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older

          2. Documented diagnosis of CF

          3. Acute pulmonary exacerbation as the primary reason for admission to the hospital with
             requirement to receive systemic antibiotic treatment

          4. If female, subjects must be non-pregnant and non-lactating. Females can be either not
             of a child-bearing potential or if of a child-bearing potential, on acceptable modes
             of birth control such as abstinence from sexual intercourse, oral/parenteral
             contraceptives, or barrier method

        Exclusion Criteria:

          1. History of any moderate or severe hypersensitivity or allergic reaction to any
             Î²-lactam antibiotic (a history of mild rash to a cephalosporin followed by uneventful
             re-exposure is not a contraindication)

          2. Prior (within 24 hours of first dose of study drug) or concomitant receipt of
             piperacillin/tazobactam or probenecid

          3. History of lung transplant

          4. Moderate to severe renal dysfunction defined as a creatinine clearance &lt; 50 mL/min (as
             calculated by the Cockcroft-Gault equation using actual body weight) or requirement
             for continuous renal replacement therapy or hemodialysis

          5. A hemoglobin less than 8 gm/dl at baseline

          6. Any rapidly-progressing disease or immediately life-threatening illness (defined as
             imminent death within 48 hours in the opinion of the investigator)

          7. Any condition or circumstance that, in the opinion of the investigator, would
             compromise the safety of the patient or the quality of study data

          8. Planned or prior participation in any other interventional drug study within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L Kuti, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children at Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Monogue ML, Pettit RS, Muhlebach M, Cies JJ, Nicolau DP, Kuti JL. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6578-6584. doi: 10.1128/AAC.01566-16. Print 2016 Nov.</citation>
    <PMID>27550351</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2017</results_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>Joseph Kuti</investigator_full_name>
    <investigator_title>Associate Director, Clinical and Economic Studies</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ceftolozane/Tazobactam</title>
          <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
Ceftolozane/Tazobactam: 1 hour intravenous infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ceftolozane/Tazobactam</title>
          <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
Ceftolozane/Tazobactam: 1 hour intravenous infusion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" lower_limit="18" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161.8" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine Clearance</title>
          <units>milliliters per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117.7" lower_limit="62" upper_limit="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ceftolozane Clearance</title>
        <description>This outcome determines the clearance of ceftolozane over the 8 hour dosing interval.</description>
        <time_frame>0, 1-1.08, 1.25-1.5, 2-3, 4-5, and 7-8 hours after start of final dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
Ceftolozane/Tazobactam: 1 hour intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Ceftolozane Clearance</title>
          <description>This outcome determines the clearance of ceftolozane over the 8 hour dosing interval.</description>
          <units>Liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ceftolozane Volume of Distribution (Central Compartment)</title>
        <description>This outcome determines the volume of distribution of ceftolozane over the 8 hour dosing interval.</description>
        <time_frame>0, 1-1.08, 1.25-1.5, 2-3, 4-5, and 7-8 hours after start of final dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
Ceftolozane/Tazobactam: 1 hour intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Ceftolozane Volume of Distribution (Central Compartment)</title>
          <description>This outcome determines the volume of distribution of ceftolozane over the 8 hour dosing interval.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tazobactam Clearance</title>
        <description>This outcome determines the clearance of tazobactam over the 8 hour dosing interval.</description>
        <time_frame>0, 1-1.08, 1.25-1.5, 2-3, 4-5, and 7-8 hours after start of final dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
Ceftolozane/Tazobactam: 1 hour intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Tazobactam Clearance</title>
          <description>This outcome determines the clearance of tazobactam over the 8 hour dosing interval.</description>
          <units>Liters per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.51" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tazobactam Volume of Distribution (Central Compartment)</title>
        <description>This outcome determines the volume of distribution of tazobactam over the 8 hour dosing interval.</description>
        <time_frame>0, 1-1.08, 1.25-1.5, 2-3, 4-5, and 7-8 hours after start of final dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
Ceftolozane/Tazobactam: 1 hour intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Tazobactam Volume of Distribution (Central Compartment)</title>
          <description>This outcome determines the volume of distribution of tazobactam over the 8 hour dosing interval.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.85" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ceftolozane Probability of Target Attainment at 8 mcg/ml</title>
        <description>This simulated outcome indicates the likelihood that ceftolozane will retain drug concentrations above the MIC for &gt;/= 60% of the dosing interval at an MIC of 8 mcg/ml when administered as a 3g (2g ceftolozane/1g tazobactam) every 8 hour dose infused over 1 hour. This analysis is conducted via a Monte Carlo simulation using the population pharmacokinetic parameter estimates and dispersion from the 20 participants who contributed pharmacokinetic data to the study.</description>
        <time_frame>24 hours</time_frame>
        <population>The results of this analysis are based on 5000 simulated patients with the same pharmacokinetics to the 20 enrolled participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ceftolozane/Tazobactam</title>
            <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
Ceftolozane/Tazobactam: 1 hour intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Ceftolozane Probability of Target Attainment at 8 mcg/ml</title>
          <description>This simulated outcome indicates the likelihood that ceftolozane will retain drug concentrations above the MIC for &gt;/= 60% of the dosing interval at an MIC of 8 mcg/ml when administered as a 3g (2g ceftolozane/1g tazobactam) every 8 hour dose infused over 1 hour. This analysis is conducted via a Monte Carlo simulation using the population pharmacokinetic parameter estimates and dispersion from the 20 participants who contributed pharmacokinetic data to the study.</description>
          <population>The results of this analysis are based on 5000 simulated patients with the same pharmacokinetics to the 20 enrolled participants.</population>
          <units>percent of simulated population</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability (Changes in Serum Chemistry, Hematology and Hepatic Lab Values, as Well as Reported Adverse Events)</title>
        <description>This outcome will assess the safety and tolerability of ceftolozane/tazobactam in adults with CF after 4-6 doses, as measured by changes in serum chemistry, hematology and hepatic lab values, as well as reported adverse events by patients and providers.</description>
        <time_frame>3 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the course of the 3 day study.</time_frame>
      <desc>Laboratory (chemistry, complete blood count, liver function tests, urinalysis) were completed systematically prior to first dose and within 24 hours after completion of the final pharmacokinetic blood sample. All other adverse events collected when reported by the participant or during daily physical examination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ceftolozane/Tazobactam</title>
          <description>Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
Ceftolozane/Tazobactam: 1 hour intravenous infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Function Test Elevation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Type I Hypersensitivity Reaction</sub_title>
                <description>Chest tightness and tongue swelling after receipt of first dose.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joseph L. Kuti, PharmD</name_or_title>
      <organization>Hartford Hospital</organization>
      <phone>860-972-3612</phone>
      <email>joseph.kuti@hhchealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

